EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Cost-Effectiveness Analysis of Hepatic Arterial Chemotherapy for Advanced Hepatocellular Carcinoma in China: A Comparative Analysis of HAIC-FO and Sorafenib

Jie Gao, Shu Liu, Shao-Jun Li, Rui Wang, Zeng-Hui Meng, Xiang-Shuo Kong

Medical Science Monitor · 2024

DOI: 10.12659/msm.944526 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Medical Science Monitor, 2024. Verfasst von Jie Gao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary & Pancreatic & Spleen Surgery, Yantai Yuhuangding Hospital, The Affiliated Hospital of Qingdao University, Yantai, Shando…. Hauptthemen laut MEDLINE: Sorafenib, Cost-Benefit Analysis, Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND The FOHAIC-1 trial showed hepatic arterial infusion chemotherapy with infusional fluorouracil, leucovorin, and oxaliplatin (HAIC-FO) improved survival, compared with sorafenib, in patients with advanced hepatocellular carcinoma (HCC). The aim of this study was to conduct a cost-effectiveness comparison between HAIC-FO and sorafenib from the perspective of the Chinese healthcare system. MATERIAL AND METHODS The economic evaluation was conducted between July 2023 and February 2024, spanning a 10-year investment horizon. A Markov model was developed to perform a cost-effectiveness analysis of HAIC-FO vs sorafenib. Health states incorporated in the model comprised progression-free disease, progressed disease, and death. Transition probabilities were derived from data obtained from the FOHAIC-1 trial. Incremental cost-effectiveness ratio (ICER) was calculated to evaluate cost-effectiveness. Additionally, one-way and probabilistic sensitivity analyses assessed the model's robustness. RESULTS The HAIC-FO group accrued a total cost of $22,781, whereas the sorafenib group totaled $18,795. In terms of effectiveness, the HAIC-FO group achieved 1.06 quality-adjusted life years (QALYs), whereas the sorafenib group attained 0.65 QALYs. Compared with sorafenib, HAIC-FO yielded an additional 0.41 QALYs at a cost of additional $3,985, resulting in an incremental cost of $9,720 per QALY gained. The one-way sensitivity analysis revealed the final ICER remained below the willingness-to-pay (WTP) threshold of $30,492 per QALY, when considering parameter fluctuations. Additionally, probabilistic sensitivity analysis indicated a 99.8% probability that the ICER for HAIC-FO compared with sorafenib would fall below the WTP threshold. CONCLUSIONS Compared with sorafenib, HAIC-FO emerged as a cost-effective first-line treatment option for patients facing advanced HCC in China.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SorafenibCost-Benefit AnalysisCarcinoma, HepatocellularLiver NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsQuality-Adjusted Life YearsOxaliplatinHumansChinaFluorouracilMarkov ChainsLeucovorinHepatic ArteryInfusions, Intra-ArterialMaleAntineoplastic AgentsFemaleCost-Effectiveness Analysis

Substanzen

SorafenibOxaliplatinFluorouracilLeucovorinAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Hepatobiliary & Pancreatic & Spleen Surgery, Yantai Yuhuangding Hospital, The Affiliated Hospital of Qingdao University, Yantai, Shandong, China.
  • Department of Oncology, Yantai Yuhuangding Hospital, The Affiliated Hospital of Qingdao University, Yantai, Shandong, China.
  • Department of Oncology, Fushan District People's Hospital, Yantai, Shandong, China.

Zitieren

APA

Gao, J., Liu, S., Li, S. J., Wang, R., Meng, Z. H., & Kong, X. S. (2024). Cost-Effectiveness Analysis of Hepatic Arterial Chemotherapy for Advanced Hepatocellular Carcinoma in China: A Comparative Analysis of HAIC-FO and Sorafenib. Medical Science Monitor. https://doi.org/10.12659/msm.944526

Vancouver

Gao J, Liu S, Li SJ, Wang R, Meng ZH, Kong XS. Cost-Effectiveness Analysis of Hepatic Arterial Chemotherapy for Advanced Hepatocellular Carcinoma in China: A Comparative Analysis of HAIC-FO and Sorafenib. Medical Science Monitor. 2024. doi:10.12659/msm.944526

BibTeX
@article{Gao2024,
  author = {Gao, Jie and Liu, Shu and Li, Shao-Jun and Wang, Rui and Meng, Zeng-Hui and Kong, Xiang-Shuo},
  title = {Cost-Effectiveness Analysis of Hepatic Arterial Chemotherapy for Advanced Hepatocellular Carcinoma in China: A Comparative Analysis of HAIC-FO and Sorafenib},
  journal = {Medical Science Monitor},
  year = {2024},
  doi = {10.12659/msm.944526}
}
Kostenlos starten →